Alzheimer’s disease (AD) is a neurodegenerative disease afflicting many people worldwide. As the specific biomarker, beta amyloid (Aβ) is considered to serve a central role in the progress of AD. To discover effective therapy for AD, esculetin was investigated using SH-SY5Y cells to evaluate its protective effects against the neurotoxicity induced by Aβ25-35. As a result, esculetin can improve the viability of SH-SY5Y cells injured by Aβ25-35 (58.0%, 66.1% and 82.1% at 0.1, 1 and 10 μM vs 49.5% at 0 μM). Further investigation has demonstrated the protective effects of esculetin at different concetrations of 0.1, 1 and 10 μM are associated with its inhibition of oxidative stress and apoptosis in SH-SY5Y cells, which is more observable especially at both 1 and 10 μM. These observations can give evidences for the following investigation in vivo and discovery of novel preventive method for AD.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.